Craig Fenwick

Craig Fenwick is a research scientist and director at CHUV | Lausanne University Hospital, where they focus on the development of novel immunotherapeutic agents and broadly neutralizing antibodies targeting HIV and other infectious diseases. Since 2013, Craig has been leading various research initiatives, including the discovery of an innovative class of anti-PD-1 antibodies and participating in significant international projects funded by the Bill and Melinda Gates Foundation. With a strong background in immunobiology and biochemistry, Craig earned a PhD from Concordia University and completed post-doctoral studies at Yale University. Prior to their current role, they were involved in HIV integrase project developments at Boehringer Ingelheim Pharmaceuticals, contributing to clinical trials and drug development.